A Phase 2 interventional study of treprostinil diethanolamine in Systemic Sclerosis, sponsored by United Therapeutics. Terminated at 26 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-18.
Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Scleroderma, Systemic with a site in United States — 40 open to participants now, 52 under way, 6 of them phase 3. Scleroderma, Systemic · United States.
Among the 165 studies in Scleroderma, Systemic with a site in United States, this one is the 33rd largest by enrollment of the 142 interventional ones that give a count, is one of 5 that started in 2009, is one of 54 in phase 2, and was the 34th registered.
613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.
Browse Scleroderma, Systemic studies →40 of the 165 studies in Scleroderma, Systemic with a site in United States are open now. Recruiting first, the newest first:
Stephan Grupp MD PhD · Sites in United States
Ages 8–25
Fate Therapeutics · Sites in United States
Ages 18–70
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 42 more countries
Ages 18+
Miltenyi Biomedicine GmbH · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 74 · Phase 3 17 · Phase 4 3
First in 1992; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 115 is above the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 34 across the 142 interventional studies, 67 across the 22 observational. Of the 104 that completed or were terminated, 56 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
69 of 165 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
United Therapeutics has 3 studies filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
15 of the studies in Scleroderma, Systemic with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06195072Scleroderma Research Foundation, Inc.Platform Clinical Study for Conquering Scleroderma | 2026-11 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT04380831City of Hope Medical CenterTBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis | 2026-12-22 |
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 165 studies in Scleroderma, Systemic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This open label extension trial will allow ongoing treatment of subjects who participated in the randomized controlled trials, and will provide long term information about the safety of treprostinil diethanolamine SR in subjects with SSc and digital ulcers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose (MTD).
Drug: treprostinil diethanolamine
sustained release tablet; BID dosing; up to 16 mg BID
Net Ulcer Burden- Mean Change From Time of Study Entry for Each Scheduled Visit Assessment
Net ulcer burden at any given assessment was defined as the number of "new" or "active" ulcers at that assessment, plus the number of "indeterminate" ulcers at that assessment that had previously been classified as either "active" or "new" at any earlier assessment during the study. The mean change in net ulcer burden from time of study entry was summarized for each scheduled visit assessment.
Time frame: Baseline and Months 1, 3, 6, 9, 12, and 18
Total Ulcer Number- Mean Change From Time of Study Entry for Each Scheduled Visit Assessment
The total ulcer number includes all ulcers designated as "active", "indeterminate", or "new" for a given visit. The mean change in the total number of ulcers present from time of study entry was summarized for each scheduled visit assessment.
Time frame: Baseline and Months 1, 3, 6, 9, 12, and 18
Formation of New Ulcers
The number and percentage of subjects who developed new ulcers during the study were summarized.
Time frame: 18 months (or last study visit)
Patient Function and QOL Measure: Scleroderma Health Assessments Questionnaire (SHAQ)- Mean Change From Study Entry in SHAQ Component Scores at Each Scheduled Assessment
The SHAQ consists of 20 health assessment questionnaire questions with integer responses of 0 (without any difficulty) to 3 (unable to do), and five scleroderma-specific visual analog scale (VAS) domains (Overall Disease Activity, Raynaud's Phenomenon, Finger Ulcers, Breathing, and Intestinal Problems) with values ranging from 0.0 to 15.0 centimeters. The questions are divided into eight component domains: Dressing \& Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each domain score is calculated by summing the domain responses and dividing by the number of questions in that domain. Each VAS domain score is calculated by dividing the value in centimeters by 5. SHAQ component and VAS domain score ranges from 0 (least limitation) to 3 (most limitation). The aggregate SHAQ score is calculated by dividing the sum of all domain scores by 13, with a score ranging from 0 (least limitation) to 3 (most limitation).
Time frame: Baseline and Months 1, 3, 6, and 12
Patient Function and Quality of Life Measure: Cochin Hand Function Scale (CHFS)-Mean Change From Study Entry in CHFS Score at Each Scheduled Assessment
The CHFS score is derived from 18 validated questions that assess functional disability and handicap due to hand involvement in rheumatoid arthritis. Each answer is scored on a scale with possible integer responses of 0(without difficulty) to 5 (impossible). The CHFS score is simply the sum of all 18 questions, divided by the number of questions actually answered, multiplied by 18. At least 10 of the 18 questions must have been answered in order for CHFS to be calculated. Therefore, CHFS score values can range from 0 (least limitation) to 90 (most limitation), with improvements in function or reduction of limitation indicated a decreased score value. The mean change from study entry in CHFS scores at each scheduled assessment are summarized.
Time frame: Baseline and Months 1, 3, 6, and 12
Subjects were recruited to enroll in 26 centers in the US, Canada, and the UK in this open-label trial within 14 days of completion of TDE-DU-201. Subjects who prematurely terminated the previous controlled trial were not eligible. Data from the final study visit of the previous trial served as Baseline data and subject blinding was maintained.
| Milestone | Oral Treprostinil Diethanolamine |
|---|---|
| Started | 115 |
| Completed | 94 |
| Not completed | 21 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Adverse event | 9 |
| Withdrew: Death | 1 |
| Withdrew: Pregnancy | 1 |
The SHAQ consists of 20 health assessment questionnaire questions with integer responses of 0 (without any difficulty) to 3 (unable to do), and five scleroderma-specific visual analog scale (VAS) domains (Overall Disease Activity, Raynaud's Phenomenon, Finger Ulcers, Breathing, and Intestinal Problems) with values ranging from 0.0 to 15.0 centimeters. The questions are divided into eight component domains: Dressing \& Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Each domain score is calculated by summing the domain responses and dividing by the number of questions in that domain. Each VAS domain score is calculated by dividing the value in centimeters by 5. SHAQ component and VAS domain score ranges from 0 (least limitation) to 3 (most limitation). The aggregate SHAQ score is calculated by dividing the sum of all domain scores by 13, with a score ranging from 0 (least limitation) to 3 (most limitation).
| units on a scale | Oral Treprostinil Diethanolamine |
|---|---|
| Month 1 | -0.01 ± 0.21 |
| Month 3 | 0.02 ± 0.23 |
| Month 6 | 0.02 ± 0.28 |
| Month 12 | -0.04 ± 0.27 |
Net ulcer burden at any given assessment was defined as the number of "new" or "active" ulcers at that assessment, plus the number of "indeterminate" ulcers at that assessment that had previously been classified as either "active" or "new" at any earlier assessment during the study. The mean change in net ulcer burden from time of study entry was summarized for each scheduled visit assessment.
| ulcers | Oral Treprostinil Diethanolamine |
|---|---|
| Month 1 | -0.77 ± 1.61 |
| Month 3 | -0.52 ± 2.02 |
| Month 6 | -0.32 ± 1.19 |
| Month 9 | -0.52 ± 1.53 |
| Month 12 | -0.64 ± 1.20 |
| Month 18 | -1.67 ± 0.58 |
The CHFS score is derived from 18 validated questions that assess functional disability and handicap due to hand involvement in rheumatoid arthritis. Each answer is scored on a scale with possible integer responses of 0(without difficulty) to 5 (impossible). The CHFS score is simply the sum of all 18 questions, divided by the number of questions actually answered, multiplied by 18. At least 10 of the 18 questions must have been answered in order for CHFS to be calculated. Therefore, CHFS score values can range from 0 (least limitation) to 90 (most limitation), with improvements in function or reduction of limitation indicated a decreased score value. The mean change from study entry in CHFS scores at each scheduled assessment are summarized.
| units on a scale | Oral Treprostinil Diethanolamine |
|---|---|
| Month 1 | -1.1 ± 9.7 |
| Month 3 | -1.2 ± 8.7 |
| Month 6 | -1.0 ± 9.3 |
| Month 12 | -2.8 ± 9.7 |
The total ulcer number includes all ulcers designated as "active", "indeterminate", or "new" for a given visit. The mean change in the total number of ulcers present from time of study entry was summarized for each scheduled visit assessment.
| number of ulcers | Oral Treprostinil Diethanolamine |
|---|---|
| Month 1 | -0.23 ± 1.36 |
| Month 3 | -0.24 ± 1.99 |
| Month 6 | -0.21 ± 1.21 |
| Month 9 | -0.46 ± 1.57 |
| Month 12 | -0.61 ± 1.20 |
| Month 18 | -1.67 ± 0.58 |
The number and percentage of subjects who developed new ulcers during the study were summarized.
| participants | Oral Treprostinil Diethanolamine |
|---|---|
| No new ulcers | 48 |
| At least one new ulcer formed | 63 |
| Indeterminate / missing data | 4 |
Collected over 48 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Treprostinil Diethanolamine | — | 17/115 (14.8%) | 113/115 (98.3%) |
| Event | Oral Treprostinil Diethanolamine |
|---|---|
| GastroenteritisInfections and infestations | 6/115 |
| AnemiaBlood and lymphatic system disorders | 2/115 |
| Skin ulcerSkin and subcutaneous tissue disorders | 2/115 |
| Renal failure acuteRenal and urinary disorders | 2/115 |
| Infected skin ulcerInfections and infestations | 1/115 |
| InfectionInfections and infestations | 1/115 |
| OsteomyelitisInfections and infestations | 1/115 |
| PneumoniaInfections and infestations | 1/115 |
| Respiratory tract infectionInfections and infestations | 1/115 |
| PancytopeniaBlood and lymphatic system disorders | 1/115 |
| Event | Oral Treprostinil Diethanolamine |
|---|---|
| HeadacheNervous system disorders | 74/115 |
| DiarrheaGastrointestinal disorders | 52/115 |
| NauseaGastrointestinal disorders | 39/115 |
| FatigueGeneral disorders | 36/115 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 29/115 |
| Pain in jawMusculoskeletal and connective tissue disorders | 29/115 |
| FlushingVascular disorders | 26/115 |
| DizzinessNervous system disorders | 22/115 |
| Infected skin ulcerInfections and infestations | 20/115 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 19/115 |
Efficacy was assessed using data obtained at each visit, if available, from all subjects enrolled in this study. Assessments performed after discontinuation of study drug were excluded from the summaries. All subjects who had at least one dose of study drug documented were included in the safety analysis population.
| Age, Continuous(years) | Oral Treprostinil Diethanolamine |
|---|---|
| Mean | 50 (21 to 82) |
| Sex: Female, Male(Participants) | Oral Treprostinil Diethanolamine |
|---|---|
| Female | 88 |
| Male | 27 |
| Race/Ethnicity, Customized(participants) | Oral Treprostinil Diethanolamine |
|---|---|
| Asian | 4 |
| Caucasian | 97 |
| African-American | 13 |
| Native American | 1 |
| Not provided | 1 |
| Years since scleroderma diagnosis(years) | Oral Treprostinil Diethanolamine |
|---|---|
| Mean | 10.9 (0 to 35) |
| Scleroderma Classification(participants) | Oral Treprostinil Diethanolamine |
|---|---|
| Limited | 82 |
| Diffuse | 33 |
The record gives a start of Sep 2009, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 2 years 5 months after primary completion. A results delay was requested in Apr 2013.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil